Related Experiment Video
Updated: Apr 23, 2026
08:18
Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
Published on: July 27, 2022
1.3K
Dry powder formulation of simvastatin
Alaa S Tulbah1, Hui Xin Ong, Lucy Morgan
1Sydney University, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, Respiratory Technology , Sydney, NSW 2037 , Australia daniela.traini@sydney.edu.au.
Expert Opinion on Drug Delivery
|September 23, 2014
Summary
A new dry powder inhaler (DPI) formulation of simvastatin (SV) is safe and effective for respiratory delivery. This simvastatin inhalation therapy reduces mucus production and shows potential for treating lung diseases.
Area of Science:
- Pharmaceutical Sciences
- Respiratory Medicine
- Drug Delivery
Background:
- Simvastatin (SV) is a statin drug with potential anti-inflammatory properties.
- Developing inhaled drug delivery systems can enable localized treatment of respiratory diseases.
- Dry powder inhalers (DPIs) offer an efficient method for delivering inhaled medications.
Purpose of the Study:
- To develop a dry powder inhaler (DPI) formulation of simvastatin (SV).
- To evaluate the effects of inhaled simvastatin on the respiratory epithelium.
- To assess the potential of SV DPI for treating respiratory conditions.
Main Methods:
- Micronized simvastatin (SV) was prepared using dry jet-milling.
- Characterization included particle size, morphology, stability, and aerosol deposition.
- In vitro studies assessed cell viability, cilia beat activity, epithelial cell transport, and mucus secretion.
Main Results:
- The simvastatin (SV) DPI formulation exhibited appropriate particle size and aerosol performance for inhalation.
- The formulation was non-toxic to pulmonary epithelial cells and did not impair cilia beat activity.
- Simvastatin (SV) penetrated airway epithelial cells, was converted to its active metabolite, and reduced mucus production.
Conclusions:
- Inhaled simvastatin (SV) demonstrates potential as a localized therapy for respiratory diseases.
- Its anti-inflammatory effects and mucus-reducing properties are beneficial for conditions like COPD, cystic fibrosis, and bronchiectasis.
- This simvastatin (SV) DPI formulation offers a promising new treatment approach for chronic lung diseases.
Related Concept Videos
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
414
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
414
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
827
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
827
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.9K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.9K
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
879
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
879